Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

2Q Revenues: $11.1 billion (-6%)

2Q Earnings: $1.3 billion (-48%)

YTD Revenues: $23.6 billion (flat)

YTD Earnings: $4.7 billion (-29%)

Comments: Worldwide pharmaceutical revenues for the quarter were $10.1 billion, down 7%. The following drugs performed well in the quarter and YTD respectively: Celebrex, 1% and 12%; Lyrica, 49% and 73%; Detrol/Detrol LA, 5% and 11%; Zyvox, 21% and 30%; Geodon/Zeldox, 8% and 14%; Caduet, 50% and 69%; Vfend, 23% and 25%; and Aromasin, 22% and 27%. 2Q revenues were hit hard by generic Zocor’s competition against Lipitor and the loss of U.S. exclusivity for Zoloft and Norvasc. Earnings were impacted by the company’s payments to Bristol-Myers Squibb regarding the apixaban collaboration.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters